Biotechnology - Therapeutics/Diagnostics

Private/independent Companies All units in USD M

Year 2013 2013 2013 2013 2013 2013 2013 2013 2013 2013 2013 2013 2014 Grand

Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Total

Total 299 172 387 599 677 353 627 419 449 682 420 328 166 5578

US 215 136 359 287 462 203 408 351 298 406 243 217 141 3726

Europe 42 29 10 248 136 121 203 37 41 155 154 78 25 1279

Rest of World 42 7 18 64 79 29 16 31 110 121 23 33 0 573

Company Name Sector Amount

mUSD

Type of

Round

Financing

Stage Ownership Country

Cara Therapeutics Inc. Therapeutics/Diagnostics 55.0 Other IPO Public USA

Trevena, Inc Therapeutics/Diagnostics 64.8 Other IPO Public USA

CytRx Corporation Therapeutics/Diagnostics 74.8 Other Post-IPO Public USA

BioCryst

Pharmaceuticals, Inc.

Therapeutics/Diagnostics 2.5 Other Research

grants

Public USA

Celladon Corporation Therapeutics/Diagnostics 44.0 Other IPO Public USA

TESARO, Inc. Therapeutics/Diagnostics 100.8 Other Post-IPO Public USA

Geron Corporation Therapeutics/Diagnostics 90.0 Other Post-IPO Public USA

Dicerna

Pharmaceuticals, Inc.

Therapeutics/Diagnostics 90.0 Other IPO Public USA

Igenica, Inc. Therapeutics/Diagnostics 14.0 Series C /

3. Round

Equity -

Second

stage

Private /

independent

USA

SQI Diagnostics Inc. R&D Services 1.2 Other Post-IPO Public Canada

MYOS Corporation Biotechnology - other 4.7 Other Post-IPO Public USA

Augurix SA Medical Technology 3.3 Other Equity -

Later

stage

Private /

independent

Switzerland

Ceres, Inc. Biotechnology - other 20.0 Other Post-IPO Public USA

Epizyme®, Inc. Therapeutics/Diagnostics 140.0 Other Post-IPO Public USA

TONIX Pharmaceuticals

Holding Corp.

Therapeutics/Diagnostics 43.5 Other Post-IPO Public USA

Akers Biosciences, Inc. Medical Technology 15.0 Other Post-IPO Public USA

Genmab A/S Therapeutics/Diagnostics 182.3 Other Post-IPO Public Denmark

Microvi Biotechnologies

Inc.

Biotechnology - other 1.5 Other Research

grants

Private /

independent

USA

Keryx

Biopharmaceuticals, Inc.

Therapeutics/Diagnostics 100.1 Other Post-IPO Public USA

NanoString

Technologies, Inc.

R&D Services 55.0 Other Post-IPO Public USA

Acceleron Pharma, Inc. Therapeutics/Diagnostics 120.0 Other Post-IPO Public USA

Nektar Therapeutics Therapeutics/Diagnostics 108.4 Other Post-IPO Public USA

Cohera Medical, Inc. Medical Technology 9.3 Series D /

4. Round

Equity -

First stage

Private /

independent

USA

Oncovet Clinical

Research

R&D Services 1.4 Series A /

1. Round

Equity -

Start-up

Public France

Synthelis R&D Services 0.8 Other Equity -

Start-up

Private /

independent

France

nLife Therapeutics Therapeutics/Diagnostics 3.1 Other Equity -

First stage

Private /

independent

Spain

GlycoMimetics, Inc. Therapeutics/Diagnostics 57.4 Other IPO Public USA

Amorfix Life Sciences

Ltd.

Therapeutics/Diagnostics 0.3 Other Other Public Canada

Receptos, Inc. Therapeutics/Diagnostics 117.4 Other Post-IPO Public USA

ProNAi Therapeutics,

Inc.

Therapeutics/Diagnostics 12.0 Series C /

3. Round

Equity -

Second

stage

Private /

independent

USA

Ivantis, Inc. Medical Technology 14.0 Series B /

2. Round

Equity -

Second

stage

Private /

independent

USA

Michelson Diagnostics

Ltd.

Medical Technology 3.3 Other Other Private /

independent

United

Kingdom

Galectin Therapeutics Therapeutics/Diagnostics 23.9 Other Post-IPO Public USA

Atara Biotherapeutics,

Inc.

Therapeutics/Diagnostics 52.0 Series B /

2. Round

Equity -

Second

stage

Private /

independent

USA

Retrophin, Inc. Therapeutics/Diagnostics 40.0 Other Post-IPO Public USA

Athersys, Inc. Therapeutics/Diagnostics 20.5 Other Post-IPO Public USA

Knome, Inc. R&D Services 13.0 Other Other Private /

independent

USA

Avelas Biosciences, Inc. Medical Technology 6.9 Series B /

2. Round

Equity -

First stage

Private /

independent

USA

GW Pharmaceuticals Therapeutics/Diagnostics 87.9 Other Post-IPO Public United

Kingdom

AC Immune SA Therapeutics/Diagnostics 22.1 Series D /

4. Round

Equity -

Start-up

Private /

independent

Switzerland

Bellicum

Pharmaceuticals, Inc.

Therapeutics/Diagnostics 14.7 Series B /

2. Round

Equity -

Second

stage

Private /

independent

USA

ImmuneXcite, Inc. Therapeutics/Diagnostics 3.6 Series B /

2. Round

Equity -

Start-up

Private /

independent

USA

Auspex Pharmaceuticals

Inc.

Therapeutics/Diagnostics 20.0 Series E /

5. Round

Equity -

Start-up

Public USA

Omicia, Inc. R&D Services 6.8 Series A /

1. Round

Equity -

First stage

Private /

independent

USA

Blueprint Medicines Therapeutics/Diagnostics 25.0 Series B /

2. Round

Equity -

Start-up

Private /

independent

USA

Halozyme Therapeutics,

Inc.

Therapeutics/Diagnostics 20.0 Other Other Public USA

Alimera Sciences, Inc. Therapeutics/Diagnostics 37.5 Other Post-IPO Public USA

DNAnexus, Inc. R&D Services 15.0 Series C /

3. Round

Equity -

Second

stage

Private /

independent

USA

Metabolon, Inc. R&D Services 15.0 Series E /

5. Round

Equity -

First stage

Private /

independent

USA

Intra-Cellular Therapies,

Inc.

Therapeutics/Diagnostics 107.5 Other Post-IPO Public USA